Cocrystal Pharma Inc - COCP STOCK NEWS

Cocrystal Pharma (Nasdaq: COCP) reported no revenues for Q3 2021, down from $489,000 a year ago. R&D expenses rose to $2.2 million, primarily due to advancements in COVID-19 and influenza programs. The net loss widened to $3.9 million, or $0.04 per share, compared to a loss of $2.7 million, or $0.05 per share, in Q3 2020. For the first nine months of 2021, the company reported no revenues versus $1.5 million in 2020, while R&D expenses increased 22% to $6.5 million. They have $61.6 million in cash and aim to advance multiple antiviral compounds into clinical development by 2022.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that its SARS-CoV-2 main protease inhibitors exhibit strong in vitro activity against various common viruses, including rhinoviruses and noroviruses. These inhibitors were developed using proprietary drug discovery technology and are advancing towards clinical trials as potential COVID-19 treatments. President Sam Lee highlighted the significance of these drugs as potential oral therapies and expressed optimism for addressing other viral diseases.

Cocrystal Pharma (Nasdaq: COCP) has submitted a pre-Investigational New Drug briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205, aiming to treat COVID-19. The submission seeks FDA guidance on clinical trial design, including preclinical studies and toxicology assessments. CDI-45205 has demonstrated potent in vitro activity against multiple SARS-CoV-2 variants and is being developed for various administration routes, with a focus on intranasal delivery. Cocrystal believes its targeted approach may offer a superior treatment solution compared to repurposed drugs.

Cocrystal Pharma (Nasdaq: COCP) announced that President Dr. Sam Lee will present new data from its COVID-19 programs at the World Antiviral Congress 2021 in San Diego on December 1, 2021, at 11:55 a.m. PST. He will discuss the discovery of oral broad-spectrum SARS-CoV-2 main protease inhibitors and advancing them to clinical development. Dr. Lee expressed gratitude for the opportunity to share exciting preclinical data regarding novel COVID-19 oral and intranasal protease inhibitors. A related press release will accompany the presentation.

Cocrystal Pharma (Nasdaq: COCP) will present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021, at 2:00 p.m. ET in Jupiter, Florida. The company recently received regulatory clearance from an Australian Human Research Ethics Committee to start a Phase 1 trial for its orally administered CC-42344 drug targeting influenza A. CFO James Martin expressed enthusiasm for discussing the company's COVID-19 antiviral programs during the presentation. A live and archived webcast will be available on the company's website.

Cocrystal Pharma (Nasdaq: COCP) has received clearance from an Australian Human Research Ethics Committee to commence a Phase 1 trial of its orally administered PB2 inhibitor CC-42344 for treating pandemic and seasonal influenza A. The randomized, double-blind, placebo-controlled study will enroll 56 healthy volunteers in Australia, focusing on the drug's safety, tolerability, and pharmacokinetics. CC-42344 exhibits exceptional antiviral activity against various influenza strains, addressing the urgent need for effective antiviral treatments.

Cocrystal Pharma, a clinical-stage biotechnology company, announced its participation in the 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast of the presentation will be available on its website starting at 1:00 a.m. ET on September 13.

Management will discuss advancements in antiviral programs targeting SARS-CoV-2 and influenza. Notable developments include the anticipated initiation of a Phase 1 trial for CC-42344 for influenza A treatments, with IND-enabling studies expected in early 2022.

Cocrystal Pharma (Nasdaq: COCP) reported no revenues for Q2 2021, down from $554,000 in Q2 2020, as Merck has assumed all development expenses for their influenza A/B program. The company's R&D expenses rose to $2.7 million, reflecting investments in COVID-19 and influenza programs. Cocrystal has $67 million in cash, sufficient to fund operations beyond 2024. Upcoming milestones include the initiation of Phase 1 clinical trials for CC-42344 and IND-enabling studies for COVID-19 antiviral compounds in 2022, after encouraging preclinical results.

Cocrystal Pharma (Nasdaq: COCP) announced that its SARS-CoV-2 protease inhibitor, CDI-45205, along with its analogs, showed strong in vitro efficacy against the Delta and Gamma variants of SARS-CoV-2. Previously, this compound demonstrated broad-spectrum activity against other variants, indicating potential as a treatment for COVID-19. Cocrystal plans to scale up synthesis for IND-enabling studies to bring CDI-45205 into clinical trials. The company's continued development of oral protease inhibitors aims to create effective coronavirus antivirals.